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AbstrAct
Introduction Atrial fibrillation (AF), the world’s most 
common arrhythmia, often goes undetected and untreated 
in low-resource communities, including India, where AF 
epidemiology is undefined. AF is an important risk factor 
for stroke, which plagues an estimated 1.6 million Indians 
annually. As such, early detection of AF and management 
of high-risk patients is critically important to decrease 
stroke burden in individuals with AF. This study aims to 
describe the epidemiology of AF in Anand District, Gujarat, 
India, characterise the clinical profile of individuals who 
are diagnosed with AF and determine the performance 
of two mobile technologies for community-based AF 
screening.
Methods This observational study builds on findings 
from a previous feasibility study and leverages two novel 
technologies as well as an existing community health 
programme to perform door-to-door AF screening for 
2000 people from 60 villages of Anand District, Gujarat, 
India using local health workers. A single-lead ECG 
and a pulse-based application is used to screen each 
individual for AF three times over a period of 5 days. 
Participants with suspected arrhythmias are followed 
up by study cardiologist who makes final diagnoses. 
Participants diagnosed with AF are initiated on treatment 
based on current anticoagulation guidelines and clinical 
reasoning.
Analytical plan Age-stratified and sex-stratified 
prevalence of AF in the Anand District will be calculated for 
sample and estimated for Anand distribution using survey 
design weights. Sociodemographic and clinical factors 
associated with AF will be evaluated using multivariable 
regression methods. Performance of each mobile 
technology in detecting AF will be evaluated using a  
12-lead ECG interpretation as the gold standard.
Ethics and dissemination This protocol was approved 
separately by the Institutional Review Board of University 
of Massachusetts Medical School and the Human 
Research Ethics Committee at Charutar Arogya Mandal. 
The findings of this study will be disseminated through 
peer-reviewed journals and scientific conferences.
bAckground
clinical and public health significance
Although atrial fibrillation (AF) is the 
world’s most common serious heart rhythm 
problem, it often goes undetected and 
untreated, particularly in low-resource 
settings like India.1–5 As such, little is 
known about the epidemiology of AF in 
India.1–3 5 However, it is estimated that 
five million Indians have AF, based on 
ageing of the Indian population and limited 
data showing that the Indian population 
is increasingly affected by AF risk factors, 
including hypertension, diabetes mellitus 
and coronary heart disease.6 The importance 
of AF to Indian public health is underscored 
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Protocol
strengths and limitations of this study
 ► The Smartphone Monitoring for Atrial fibrillation in 
Real-Time in India study represents an innovative 
screening and referral paradigm for persons living in 
low-resource settings who may have an undetected 
chronic disease.
 ► This study highlights the importance of conducting 
a feasibility study and engaging local community 
partners prior to undertaking more broad-based 
population screening efforts.
 ► Serial screening and rigorous clinical follow-ups, 
which include continuous monitoring using a 
Holter device, increase the chances of identifying 
paroxysmal atrial fibrillation (AF) events. By contrast, 
most AF screening programmes described in the 
literature rely on a single-point screening.
 ► Our efforts to characterise the clinical profile of 
participants diagnosed with AF are limited by the 
cross-sectional design of our study which prohibit 
us from drawing casual inferences.
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by an ongoing stroke epidemic with an estimated 
1.6 million Indians experiencing a stroke in 2015.7 8 AF 
is a major risk factor for stroke conferring a fivefold 
higher risk among affected individuals compared with 
those free from the arrhythmia, suggesting that AF has 
become a major public health concern in India.8–10 
Public health programmes for the routine surveillance 
of AF or other risk factors for stroke are sparse in India. 
A small proportion of Indian residents have access to 
routine cardiovascular care or prompt stroke treatment, 
and this subgroup is disproportionately clustered in urban 
and metropolitan cities. In light of the limited access to, 
and out-of-pocket costs associated with, stroke treatment, 
AF screening and treatment represent an appealing 
method for primary stroke prevention in rural India.7 
Targeted AF screening has been employed successfully in 
high-income countries, such as the UK and Australia,11–14 
but there are no major systematic efforts to screen for AF 
in low-income and middle-income countries. Further-
more, oral anticoagulation to prevent stroke is an effec-
tive therapy for patients with AF, but solutions are needed 
to assist those with limited means to pay for this treat-
ment.5 15–17 Another major barrier to AF screening has 
been the resource intensiveness of performing conven-
tional 12-lead ECG to diagnose AF.18 For these and other 
reasons, the importance of developing new, affordable, 
medical devices for AF screening that could be deployed 
in India was emphasised by an National Heart, Lung, and 
Blood Institution Expert panel and at the 2008 Hyder-
abad workshop.5
In this manuscript, we present an innovative commu-
nity-based study called Smartphone Monitoring for 
Atrial fibrillation in Real-Time—India (SMART-India). 
Our approach deploys two novel smart device-based 
arrhythmia analysis technologies for AF screening using 
an existing network of community-health workers in 
rural Western India, medical professionals and provin-
cial health leaders, and builds on a foundational feasi-
bility assessment conducted in Gujarat, India. The 
SMART-India study is supported by our interdisciplinary 
Indo-US research team that has an ongoing collabora-
tion between investigators with a proven track record 




Kardia’s Food and Drug Administration (FDA) approved 
AliveCor device records a single-lead ECG signal from the 
user. Participants place two or three fingers of their right 
hand and left hand on the two electrodes on the AliveCor 
device. Finger contact activates the recording of bipolar 
lead 1 and the signal is transmitted from the device to 
the iPhone by frequency modulation of an ultrasound 
signal.20 An automated algorithm, developed to interpret 
one’s cardiac rhythm, produces noise-filtered traces and 
a computer-averaged complex for arrhythmia diagnosis 
based on two criteria: p-wave absence and R–R interval 
irregularity. The developers of AliveCor device reported 
a sensitivity of 0.98 and specificity of 0.97 for the detec-
tion of AF against the gold-standard 12-lead ECG in the 
controlled developmental environment.20
Pulse-based ANAND application
Our team has developed a novel pulse-based approach 
for detecting arrhythmias that does not require addi-
tional hardware. This experimental Automated Novel 
Atrial fibrillation Noninvasive Detection (ANAND) 
application, named after our study site in India, builds 
on our previous USA-based algorithm to identify pulse 
complexity and irregularity.21 22 Participants are asked 
to hold the mobile phone in their hand, with their right 
first finger or second finger over the standard camera 
and lamp. The flashlight illuminates the finger and 
the pulse waveform is recorded for up to 2 min, with 
30 s being needed in most cases to complete a rhythm 
analysis. The ANAND algorithm performs two calcu-
lations to approximate a person’s cardiac rhythm: (1) 
root mean square of successive difference of RR inter-
vals to quantify variability between RR peaks and (2) 
Shannon entropy (or turning point ratio) to charac-
terise the complexity of variability between two consec-
utive segments of 14 RR peaks.22 The results from this 
automated algorithm’s calculation on the waveform 
are classified as normal sinus rhythm, possible AF or 
indeterminate.21 The preceding prototype for ANAND 
application (app) was tested in a clinical environment 
and compared its performance against a manually adju-
dicated ECG reading demonstrating a sensitivity of 0.97 
and a specificity of 0.94 for the detection of AF. This 
ANAND app is not commercially available and differs 
from the early prototype in two main aspects: a shorter 
duration of pulse recording and optimised threshold 
for RR variability and Shannon entropy based on data 
collected from our feasibility study.23
Feasibility study
In mid-2015, a feasibility study was undertaken in rural 
Western India to screen for AF using the two smart-
phone-based technologies: (1) the AliveCor device and 
(2) the ANAND app. Our primary objective for this study 
was to help identify the potential barriers and facilitators 
for conducting AF screening on a larger, more diverse 
and representative sample.
Our field staff for each village consisted of two under-
graduate medical students who were trained in collecting 
field observation notes (online supplementary appendix 
A), a research coordinator, two social workers who were 
trained in administering questionnaires and using mobile 
technology to screen for AF and a local village health 
worker to help identify residents of the given village 
who meet the eligibility criteria. We screened a total of 
354 participants aged 50 years and above, across six villages 
in Anand District in Gujarat. Each participant in this pilot 
study was screened for 2 min using both technologies for five 
consecutive days. Data was collected over a 6-week period. 
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Table 1 Findings from the feasibility study and corresponding modifications in the SMART-India study
Theme Findings Modification
Sampling strategy  ► Recruiting an equal distribution of participants across the 
different age–sex stratum was difficult
 ► Approaching households in a random fashion to recruit 
participants resulted in a bias towards selection of middle-
aged female and older participants who were more likely to 
be present at home and available for screening
Use of census data to recruit an age-
representative and sex-representative 
sample through stratified sampling to 
mitigate potential selection bias
Motion artefact  ► Participants found it difficult to maintain steady hands 
while placing their fingers on the AliveCor case without 
additional support
 ► Participants found 2 min screening period to be too long to 
maintain steady hands
 ► Use of clipboards to stabilise 
participants’ hands
 ► Shorter recording time: 60 s (AliveCor) 
and 90 s (ANAND)
Screening protocol  ► A single time-point screening underestimated true AF 
prevalence (owing to paroxysmal AF)
 ► Five screenings in a week were time consuming and led to 
participant attrition
Three screenings over the course of 
5 days to account for paroxysmal events 
and prevent study attrition
Data management  ► Research staff had difficulties uploading ECG tracings for 
adjudication in a timely manner
 ► Questionnaires in the field could not be entered using 
smartphones and tablets due to poor internet connectivity
 ► Development of a web platform to 
assist with sharing of de-identified ECG 
recordings
 ► Use of an off-line smartphone-based 
application
AF, atrial fibrillation; ANAND, Automated Novel Atrial fibrillation Noninvasive Detection; SMART-India, Smartphone Monitoring 
for Atrial fibrillation in Real-Time—India.
Key findings from field observation notes and in-depth 
interviews of the field staff are described in table 1. The 
sample prevalence of AF using the clinician’s adjudication 
of single-lead ECG recordings from the AliveCor device was 
found to be 5.1% (95% CI 2.7% to 8.7%).24
community-based approach
Our approach builds on a long-standing collaboration 
between the University of Massachusetts Medical School 
and Charutar Arogya Mandal (CAM), a tertiary care 
hospital and medical college in rural Western India.19 
This collaboration, which we have called Research and 
Advocacy for Health in India (RAHI: Hindi word for 
pathfinder), is grounded in extensive interactions with 
the local Indian communities. As we have described else-
where,19 the research priorities of our collaboration and 
our studies are informed by community health needs 
assessments. The subsequent collaborative research plans 
are designed based on a dynamic process that incorpo-
rates feedback collected through iterations of commu-
nity engagement activities. We discussed our findings 
from the feasibility study with the Community Extension 
Department at CAM, local community health workers and 
CAM clinical staff. Based on their feedback, we decided 
to leverage an existing CAM programme called SPARSH 
(Shree Krishna Hospital Programme for Advancement of 
Rural and Social Health; Hindi word for touch) to facili-
tate the community-based screening for AF.
SPARSH is a 5-year joint project by CAM’s Community 
Extension Department and Shree Krishna Hospital that 
is focused on non-communicable diseases. The ultimate 
goal of the SPARSH programme is to develop a three-tier 
healthcare system that reaches local villages at the grass-
roots level. A total of 60 villages from the administrative 
district of CAM are enrolled in the SPARSH programme. In 
this programme, local village health workers, representing 
the first tier of three, are used to identify and register 
patients through an annual household survey, monthly 
camps and standardised screening programmes. These 
patients are then referred to the remote extension centres, 
representing the second tier of the SPARSH programme, 
where a medical officer assesses, educates and prescribes 
necessary treatment. Additionally, if a medical officer 
determines that further work-up is required, the patient is 
referred to the Shree Krishna Hospital, third tier, located 
at the main CAM campus. At the time of implementation 
of the SMART-India study, this three-tier referral system was 
not in place and, therefore, SMART-India relied exclusively 
on the census collected by village health workers as part of 
their annual household survey.
MEthods/dEsIgn
objectives
Box lists the primary objectives of the SMART-India 
study. These objectives are informed by the feasibility 
study, AF-screening technology and community-based 
approach.
study design
Figure 1 provides an overview of the SMART-India study 
protocol from the perspective of prospective participants. 
The SMART-India study is a cross-sectional screening 
of 2000 adult men and women aged 45 years and older 
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box study aims for Smartphone Monitoring for Atrial 
fibrillation in Real-Time—India
 ► Aim 1: Describe the epidemiology of atrial fibrillation (AF) in Anand 
District, Gujarat, India. Screen 2000 residents of Gujarat to describe 
the age-stratified and sex-stratified prevalence of AF.
 ► Aim 2: Characterise the profile of individuals who are diagnosed 
with AF. Compare clinical findings, quality of life and risk factors 
of participants who are diagnosed with AF with those who do not 
have AF.
 ► Aim 3: Determine the performance of two mobile technologies 
for community-based AF screening. Determine the sensitivity, 
specificity and discriminative ability of the AliveCor and Automated 
Novel Atrial fibrillation Non-invasive Detection’s automated AF 
detection algorithm to the gold-standard 12-lead ECG as well as 
interpretation by a trained clinician.
Figure 1 An overview of SMART-India study protocol for community-based screening of AF and referral for clinical follow-up 
in rural Western India. AF, atrial fibrillation; ANAND, Automated Novel Atrial fibrillation Noninvasive Detection; app, application; 
FDA, Food and Drug Administration; SMART-India, Smartphone Monitoring for Atrial fibrillation in Real-Time—India; SPARSH, 
Shree Krishna Hospital Programme for Advancement of Rural and Social Health.
from 60 villages participating in the SPARSH programme 
paired with a clinical follow-up of all participants with 
abnormal screenings. Each participant is screened three 
times over the course of 5 days to account for potential 
paroxysmal AF presentation.
staff training
The SMART-India study is supported by 4 field workers, 
1 clinical coordinator, 1 project supervisor and 50 village 
health workers. The field workers and clinical coordinator 
received 2 weeks of training in the use of smartphones and 
devices to administer questionnaires to surveyed individuals 
and perform screening for AF. Additionally, the five staff 
members worked with the investigators to develop stan-
dardised operating procedures for their tasks. Following 
training, the five team members collaborated with the 
study investigators to organise a 1-hour orientation for 
the 60 village health workers. Participants from 50 villages 
took part in this study, while volunteers from the other 10 
villages had participated in the feasibility study described 
earlier. Training provided the village health workers with 
information about the study, their roles and introduction 
to the rest of the study team. During the orientation, village 
health workers indicated that navigating the village to iden-
tify participants listed in the roster would be the primary 
time constraint. Thus, we divided the four field workers 
into two teams and proceeded with simultaneous screen-
ings in two separate villages to enhance efficiency. One of 
the Indian co-investigators on the team fulfilled the role of 
project supervisor.
Questionnaire translation and testing
We use standardised questionnaires to collect information 
about participants’ demographic characteristics, lifestyle 
risk factors, past medical history, family history, physical 
activity, medication, AF-related symptoms and healthcare 
usage at the time of the first screening (table 2). Addition-
ally, we administer an exit survey to ascertain participants’ 
feedback about the screening technology and a clinical 
follow-up survey to assess participants’ quality of life and 
cardiovascular-related factors. All questionnaires were 
translated to Gujarati and interpreted by several volun-
teers representing a wide range of literacy (ie, attending 
physician, healthcare worker, research coordinator, village 
health worker and community representative). The inter-
pretations of questions and responses were back-trans-
lated and compared with the original questionnaire in 
English. Common themes for discordance between the 
original and back-translated forms were identified and 
used to modify the original questionnaire to accommo-
date the cultural context. This process was repeated until 
there was convergence between the two versions. All 
translations were done by certified professional translator 
services in Gujarat, India.
data management
Figure 2 describes the data management strategy for 
SMART-India study. Based on our prior experience, we 
use the Magpi platform to administer questionnaire-based 
surveys to the participants. Magpi allows for off-line data 
collection in smartphones and tablets through a user-
friendly app and uploads collected data to a secure server 
once the device connects to the Internet. The files from the 
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Figure 2 An overview of data management for SMART-India study. Questionnaire data is collected using Magpi platform, 
screening files are imported through iTunes, and clinical forms as well as abnormal recordings are stored in REDCap. Logo 
credit: Magpi Inc (www.home.magpi.com); AliveCor (www.AliveCor.com); Adobe Reader (www.acrobat.adobe.com); iTunes 
(www.apple.com/itunes); REDCap (www.project-redcap.org); Stata (www.stata.com)
Table 2 Data collected using standardised questionnaires during enrolment, final screening and follow-up time points for 
Smartphone Monitoring for Atrial fibrillation in Real-Time—India study
Enrolment
Domain Variables 
  Sociodemographic characteristics Age, sex, household size, education level, occupation, caste, religion, marital status
  Financial status Household income, perceived income, perceived expenditures
  Healthcare Healthcare use, healthcare seeking behaviour, healthcare expenditures
  Lifestyle Smoking, non-smoking tobacco, alcohol, expenditures on lifestyle activities
  Physical activity Mild, moderate and high levels of activity using International Physical Activity 
Questionnaire
  Cardiovascular symptoms Palpitations, irregular heartbeats, skipped heartbeats, dizziness
  Medical history Valvular heart disease, coronary heart disease, obstructive lung disease, myocardial 
infarction, hypertension, diabetes mellitus, hypercholesterolaemia, heart failure, 
stroke, transient ischaemic attack, systemic embolism, anaemia, internal bleeding 
(intracranial, gastrointestinal or other), chronic kidney disease, congenital heart 
disease
Exit
  Technology access Cell phone ownership, cell phone with camera, smartphone use, internet usage, 
internet use to find health information
  ANAND usability Time-consuming, operational ease, understandability of results
Follow-up
  Quality of life Physical and Mental composite score using SF-12
  Need for assistance Recreational activities, travelling, shopping, preparing or eating meals, day-to-day 
activities, medication management, financial management
ANAND, Automated Novel Atrial fibrillation Non-invasive Detection; SF-12, Short Form-12 Survey.
AF screening apps (AliveCor and ANAND) are downloaded 
to a personal computer from the phones using iTunes. 
Results from the automated algorithm of AF screening 
apps and all abnormal AliveCor ECG tracings are uploaded 
to REDCap. Additionally, all data emerging from the clin-
ical follow-up, except for questionnaire-based surveys, are 
uploaded to REDCap. REDCap is used because it allows for 
file uploads and can create reports that are helpful during 
the adjudication process.
sample size calculations
Based on our calculations, a sample size of 1823 persons 
is required to estimate the prevalence of AF with 1% error 
assuming the a priori prevalence of AF to be 5% based 
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Table 3 95% CI for sensitivity and specificity by number of participants to justify the sample size of 2000 participants for the 
Smartphone Monitoring for Atrial Fibrillation in Real-Time in India (Smart-India)study (assumes 5% prevalent atrial fibrillation)
Number of participants 500 1000 2000 5000
Sensitivity (0.9) 0.69 to 0.97 0.78 to 0.97 0.82 to 0.95 0.86 to 0.93
Specificity (0.9) 0.87 to 0.93 0.88 to 0.92 0.89 to 0.91 0.89 to 0.91
Figure 3 A field worker is collecting single-lead ECG 
recording from a SMART-India participant. The participant 
is asked to place her fingers on the AliveCor device that is 
supported by a clipboard to minimise motion-noise artefact. 
The participant approved the use of this picture and provided 
consent for its use. SMART-India, Smartphone Monitoring for 
Atrial fibrillation in Real-Time—India.
on our feasibility study. The resultant stratum size of 300 
people can estimate the subpopulation prevalence of 5% 
with a 95% CI of 2.8% to 8.1%. An effective screening 
tool maximises sensitivity to avoid false-negative findings. 
Assuming a 5% prevalence of AF, a sample size of 2000 
participants (5% AF rate, n=100) or more is necessary 
to obtain a satisfactory confidence band for 90% sensi-
tivity for study aim 3 (table 3). Considering the extent 
of resources available, the study team decided to screen 
2000 adult men and women 45 years and older to accom-
plish the aims outlined in box.
community-based screening
Prescreening preparation
One week prior to screening, field workers for study 
team A and team B contact the respective village 
health workers to inform them of the screening plan. 
Both teams develop an age-stratified and sex-stratified 
recruitment roster for their respective villages based 
on the census provided by the SPARSH programme. In 
total, six strata are defined for the combination of age 
(40–55, 56–65 and 65+ years) and sex (male and female) 
categories. Teams print out recruitment and screening 
tracking forms (online supplementary appendix B) and 
charge the smartphones and portable powerbanks for 
use during the week.
Screening protocol
Recruitment and enrolment occurs on day 1 and day 2 
of the screening process. The two study teams accom-
pany their respective village health workers to enrol 21 
willing participants in their respective villages on a daily 
basis. Each participant is screened using the AliveCor 
device for 1 min, with the AliveCor device placed on the 
clipboard (figure 3), followed by the ANAND app for 
1 min 30 s. Results are recorded in the tracking form. 
If the participant is screened for either unclassified or 
unreadable heart rhythm on AliveCor, two more attempts 
are made to obtain either a normal or possible AF auto-
mated reading. Following this screening process, each 
participant completes the enrolment questionnaire 
that is entered directly into the Magpi database by the 
field assistants. Village health workers perform random 
blood glucose testing and measured the blood pressure 
of all participants. On day 3, both field teams attempt to 
screen all 42 participants using the AliveCor device and 
ANAND app. A successful follow-up, number of attempts 
required and whether or not the screening occurred at 
home is recorded in the tracking form. On day 4 and 
day 5, the third screening for AF is again split into 2 days. 
If a participant is not available on day 3, field workers 
approach them on both days to perform a total of three 
screenings over 5 days. Thus all participants are screened 
1 and 2 days apart, unless they are unavailable during 
their follow-up screening. After the final screening was 
completed, the field workers administer an exit survey, 
and data is entered directly into Magpi forms. The results 
of all screenings are recorded on paper and entered into 
REDCap along with the AliveCor ECG recordings for 
those who have an abnormal finding.
Postscreening activities
On each of the final 2 days (day 4 and day 5) of screening, 
field workers travel back to CAM to complete data entry 
and upload all abnormal (possible AF/unclassified) 
ECG files to REDCap. All AliveCor and ANAND files are 
downloaded from the phones using iTunes. All AliveCor 
portable document formats are renamed with patient IDs 
and separated into normal results versus AF/unclassified 
results. All AF/unclassified files are uploaded to REDCap 
and flagged for adjudication. The field workers create a 
weekly report to summarise recruitment and results of 
screening and distribute it with the team (online supple-
mentary appendix C). All of the ANAND and AliveCor 
files are uploaded to a secure server to support ad hoc 
analyses for measuring the performance of the two 
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Figure 4 A flow chart describing the clinical decision-making of the study cardiologist for participants following up in clinic 
for abnormal screening results during SMART-India study. CHA2DS2-VASc, Congestive heart failure, Hypertension, Age 75+ 
years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Female sex; HbA1c, glycated haemoglobin; SMART-India, 
Smartphone Monitoring for Atrial fibrillation in Real-Time—India.
screening methods. Ultimately all data are exported to 
STATA for statistical analyses (figure 2).
clinical follow-ups
Our protocol for clinical follow-ups evolved over 
time based on feedback from the research team. The 
primary impetus behind the change in approach was 
higher than expected number of screenings that are 
classified as inconclusive and the resultant backlog 
of follow-up visits needed to understand these incon-
clusive readings. In order to facilitate prompt clin-
ical visits for high-risk participants, we introduced a 
triaging step (Modifications for follow-up scheduling) 
after reviewing the clinical charts and final diagnosis 
for the first 50 participants that were followed up in 
clinic.
Scheduling follow-ups
The clinical coordinator schedules all follow-up visits 
with village health workers. One day prior to the 
visit, the clinical coordinator informs the cardiac and 
extension departments about the number of partic-
ipants and which village health workers are coming. 
The clinical coordinator prints out the abnormal 
ECGs and paper clinical forms to prepare for the 
follow-up visit.
Follow-up protocol
The clinical coordinator meets the village health 
workers and participants at the hospital and escorts 
them to the cardiac centre. Once at the cardiac centre, 
the clinical coordinator conducts further AF screening 
using the AliveCor device and ANAND app using the 
same methodology as in the field. Subsequently, all 
participants receive a 12-lead ECG. The study cardiolo-
gist reviews all of the ECG recordings (field and clinical 
visit) and determines whether or not to pursue additional 
clinical work-up. While waiting for the cardiologist’s 
interpretation, the clinical coordinator administers the 
follow-up survey in Magpi, recorded vital information as 
measured by the nurse (height, weight, blood pressure, 
heart rate, O2 saturation, temperature) and verified the 
participants’ medical history. The cardiologists’ clinical 
decision-making is described in figure 4. If the cardiol-
ogist interprets all ECG recordings of the participant as 
showing normal sinus rhythm, no additional studies are 
ordered. If the cardiologist diagnosed the participant 
as having definite AF in any of the ECG, either in any 
of the screening ECG or in-office ECG, additional labo-
ratory investigations are performed to inform clinical 
decision-making about initiation of anticoagulation and 
management plan (figure 4). If AF was suspected on any 
of the screening ECG but a diagnosis of definite AF could 
not be made due to poor quality of ECG tracings from 
screening app, multiple atrial or ventricular premature 
complexes, or a normal sinus rhythm on the 12-lead 
ECG, the cardiologist orders 24-hour Holter monitoring 
to look for paroxysmal AF events or other abnormalities. 
Two-dimensional echocardiography is performed in 
all participants diagnosed with AF and in those having 
symptoms and/or ECG abnormalities that warrants 
for an echocardiographic examination. Decision to 
initiate anticoagulation is taken based on Congestive 
heart failure, Hypertension, Age 75+ years, Diabetes 
mellitus, Stroke, Vascular disease, Age 65-74 years, 
group.bmj.com on January 19, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Soni A, et al. BMJ Open 2017;7:e017668. doi:10.1136/bmjopen-2017-017668
Open Access 
Table 4 Validation strategy to assess performance of atrial fibrillation screening technology
Phase Screening technology Gold standard
In-field Automated Novel Atrial fibrillation Noninvasive 
Detection (ANAND) automated algorithm
AliveCor automated algorithm
Clinical adjudication of AliveCor recording from the same day
In-clinic ANAND automated algorithm
AliveCor automated algorithm
Clinical interpretation of 12-lead ECG from the same day
Female sex (CHA2DS2-VASc) score.
25 All of the clinical 
data including medications is abstracted by the clinical 
coordinator using clinical research forms.
Modifications for follow-up scheduling
A preliminary inspection of clinical follow-ups found 
that the majority are due to an ‘inconclusive’ finding of 
AliveCor ECG recording based on Kardia’s automated 
algorithm. Specifically, 44 out of the first 50 follow-ups are 
of participants whose screening was inconclusive. Out of 
these 44 participants, 41 were found to have normal sinus 
rhythm after the study cardiologist interpreted field and 
12-lead clinical ECGs. Additionally, two of the remaining 
three participants were found to have benign, non-AF 
arrhythmias. Based on these findings, we modified our 
follow-up protocol by having the study cardiologist triage 
the single-lead ECG recordings from the field prior to 
the participants’ clinical follow-ups to prioritise high-risk 
patients and rule out false-positive recordings.
data adjudication
All interpretations of ECG recordings determined as AF 
or abnormal by the AliveCor automated algorithm are 
reviewed by a separate team of trained clinicians through 
a standardised adjudication process. Two resident-level 
physicians independently review each abnormal AliveCor 
generated ECG recording using REDCap and enter their 
interpretation as either: (1) normal sinus rhythm, (2) AF 
or (3) as an other arrhythmia (free text). In the event 
of disagreement between the two reviewers, a fellow-level 
physician reviews the ECG recording.
Analytical plan
Aim 1: AF epidemiology
The gold standard of cardiologist-verified diagnoses 
of AF will be used to calculate the age-stratified and 
sex-stratified prevalence of AF in the study sample. Popu-
lation estimates will be derived from the sample preva-
lence using survey weights constructed using the census 
collected by the SPARSH programme and the Govern-
ment of India sponsored census in 2011. Three separate 
calculations will be performed to describe the overall 
prevalence of AF and separately for those with valvular AF 
and non-valvular AF.
Aim 2: Profile of patients likely to have AF
Distribution of covariates (table 1) across group of partici-
pants diagnosed with AF will be compared with those who 
were not diagnosed with AF to determine associated risk 
factors. Sensitivity analyses will be performed to rule out 
differences between the group of participants who were 
not diagnosed with AF but were followed up clinically 
in comparison with those who were never followed up. 
If meaningful differences are identified in our sensitivity 
analyses, distribution of covariates will be assessed across 
the three different groups of participants. Additionally, 
among those participants who are followed up clinically, 
differences in the distribution of clinical factors between 
the group of AF-positive and AF-negative participants 
will be assessed. For sociodemographic and clinical risk 
factors, multivariable regression techniques will be used 
to identify their conditional effects after accounting for 
other covariates. Lastly, among the participants who were 
followed up clinically, the effects of AF will be estimated by 
comparing differences in the quality of life score ((Short 
Form-12 Survey) SF-12, table 1) between groups of partic-
ipants who are diagnosed for AF versus those who do not 
have AF. Potential confounders will be identified based 
on a priori knowledge (age, sex, socioeconomic status) 
and an examination of bivariate association of sociode-
mographic factors with AF and quality of life.
Aim 3: Performance of AF-screening technology
Sensitivity, specificity and discriminative ability (receiver 
operating characteristic curve analyses) with 95% CI 
bands will be used to measure the performance of our 
AF-screening technology in field and in clinic (table 4). 
In-field performance of AF-screening technology will be 
used by comparing results from the ANAND and AliveCor 
automated algorithms with the gold standard of adjudi-
cated interpretations of the AliveCor ECG recordings. 
The clinical performance of AF-screening technology 
will be assessed by comparing results from the automated 
algorithms from both technologies with results from the 
gold-standard 12-lead ECG.
Limitations and strengths
It is important to consider that this study screens people 
of villages from rural Indian region who live in villages 
enrolled in SPARSH programme that is focused on 
addressing non-communicable diseases and its risk 
factors. Therefore, the participants recruited in this study 
may under-represent the true burden of AF risk factors 
present in rural Indian population. Additionally, ascer-
tainment of certain lifestyle-related AF risk factors is 
based on self-report, which is prone to under-reporting. 
Mobile technologies are used to perform multiple AF 
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screening to account for potentially paroxysmal nature 
of AF. This approach, although superior to single time 
point screening, is vulnerable to missing AF. However, we 
attempt to partially address this limitation by obtaining 
a 24-hour Holter recording for participants who experi-
ence rhythm abnormalities on AliveCor or 12-lead ECG 
but may not be classified as AF.
dIscussIon
The SMART-India study represents an innovative 
screening and referral paradigm for persons living in 
low-resource settings who may have an undetected chronic 
disease. Our study also highlights the importance of 
conducting a feasibility study and engaging local commu-
nity partners prior to undertaking more broad-based 
population screening efforts. Findings from this study 
will provide greater insights into the silent burden of AF 
in rural Indian communities and help identify potential 
targets for intervention to modify the ongoing epidemic 
of stroke in India. The potential public health impact of 
the SMART-India study is particularly noteworthy in light 
of a recent white paper on AF screening which reported 
that AF detected during a screening procedure is not a 
benign condition and carries a sufficient risk of stroke.14 
Further work is needed to build on the SMART-India 
study and build a nexus of providers that can help triage 
high-risk patients and further enhance the efficiency 
of a referral system for persons with suspected chronic 
disease, including cardiovascular disease. Leveraging 
existing community-based programmes, such as SPARSH, 
can help achieve this ambitious, but feasible, goal.
Ethics and dissemination
The SMART-India study was reviewed and approved 
by ethical boards from the University of Massachu-
setts Medical School (IRB number H00008089) 
and CAM (HREC number IEC/HMPCMCE/70/
Faculty/15/160/16). The primary outcomes of this study 
will be disseminated through annual scientific confer-
ences and three separate peer-reviewed publications, one 
corresponding to each objective. Additionally, the authors 
will share data with ongoing coalition efforts to better 
understand global epidemiology of AF and to guide the 
development of more robust AF screening programmes 
in resource-limited settings.
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